B-Cell Lymphoma D8227C00002 / 277659
Study #D8227C00002A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
Description
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
Sponsor: AstraZeneca
Principal Investigator: Dr. Tara Graff
Back To Clinical Trials NCI Database Entry